Payers Having More Impact On R&D, Pfizer Says; Asenapine Is Early Casualty
Executive Summary
Pfizer's termination of its codevelopment agreement with Organon for the antipsychotic asenapine is indicative of the increasingly important role payer considerations play in development decisions, Pfizer CEO Jeffrey Kindler said
You may also be interested in...
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
PDUFA Pilots: Risk/Benefit Plan Takes Off As “Continuous” Applications Stop
FDA's proposals for renewal of the Prescription Drug User Fee Act will continue the program's function as an incubator of new regulatory approaches by the agency